Jiangxi Fushine Pharmaceutical Co Ltd (300497) - Total Liabilities
Based on the latest financial reports, Jiangxi Fushine Pharmaceutical Co Ltd (300497) has total liabilities worth CN¥2.27 Billion CNY (≈ $332.16 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Jiangxi Fushine Pharmaceutical Co Ltd cash conversion from operations to assess how effectively this company generates cash.
Jiangxi Fushine Pharmaceutical Co Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Jiangxi Fushine Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 300497 financial resilience to evaluate the company's liquid asset resilience ratio.
Jiangxi Fushine Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jiangxi Fushine Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Beijing VRV Software Corp Ltd
SHE:300352
|
China | CN¥781.19 Million |
|
FLEX LNG Ltd
NYSE:FLNG
|
USA | $1.90 Billion |
|
CBIZ Inc
NYSE:CBZ
|
USA | $2.67 Billion |
|
NRW Holdings Limited
F:3NR
|
Germany | €1.09 Billion |
|
Hefei Jianghang Aircraft Equipment Corporation Ltd
SHG:688586
|
China | CN¥1.14 Billion |
|
Zhejiang Jiangshan Chemical Co Ltd
SHE:002061
|
China | CN¥60.64 Billion |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥278.25 Million |
|
dentalcorp Holdings Ltd
TO:DNTL
|
Canada | CA$1.70 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Jiangxi Fushine Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Jiangxi Fushine Pharmaceutical Co Ltd worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangxi Fushine Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangxi Fushine Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual total liabilities of Jiangxi Fushine Pharmaceutical Co Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.36 Billion ≈ $345.33 Million |
+0.50% |
| 2023-12-31 | CN¥2.35 Billion ≈ $343.63 Million |
-0.92% |
| 2022-12-31 | CN¥2.37 Billion ≈ $346.83 Million |
+34.12% |
| 2021-12-31 | CN¥1.77 Billion ≈ $258.59 Million |
+77.09% |
| 2020-12-31 | CN¥997.93 Million ≈ $146.03 Million |
-6.59% |
| 2019-12-31 | CN¥1.07 Billion ≈ $156.33 Million |
+1.76% |
| 2018-12-31 | CN¥1.05 Billion ≈ $153.62 Million |
+27.60% |
| 2017-12-31 | CN¥822.70 Million ≈ $120.39 Million |
+33.95% |
| 2016-12-31 | CN¥614.20 Million ≈ $89.88 Million |
+48.56% |
| 2015-12-31 | CN¥413.44 Million ≈ $60.50 Million |
+18.44% |
| 2014-12-31 | CN¥349.09 Million ≈ $51.08 Million |
+12.05% |
| 2013-12-31 | CN¥311.55 Million ≈ $45.59 Million |
+6.80% |
| 2012-12-31 | CN¥291.70 Million ≈ $42.69 Million |
+25.71% |
| 2011-12-31 | CN¥232.04 Million ≈ $33.96 Million |
-- |
About Jiangxi Fushine Pharmaceutical Co Ltd
Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. The company offers ß-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride… Read more